RENNOVA COMPLETES AGREEMENT TO SEPARATE ITS OFTWARE AND GENETIC DIAGNOSTICS INTERPRETATION DIVISIONS INTO INNOVAQOR, INC. (OTC: INOQ)

WEST PALM BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) — Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW) (“Rennova” or the “Company”), an owner and operator of rural hospitals in Tennessee, announces that on December 31. 2020, it completed an agreement with InnovaQor, Inc. (OTC: INOQ) (InnovaQor) a CO based public company, to merge its software and genetic testing interpretation divisions, Health Technology Solutions, Inc. (HTS) and Advanced Molecular Services Group, Inc., (AMSG) and their subsidiaries into InnovaQor. After closing these entities will operate as wholly owned subsidiaries of InnovaQor. Closing is subject to a number of customary conditions for a transaction of this nature and is intended to happen on or before January 31. 2020.

InnovaQor has previously completed a license agreement giving it certain rights to assets and technology from TPT Global Tech, Inc’s. (OTC: TPTW) proprietary live streaming communication technology. As part of the License agreement InnovaQor and TPT have agreed a development project to create a next generation telehealth type platform. It is intended to combine the TPT and Rennova assets and technology into a smart phone and computer accessible healthcare platform to facilitate a patient’s immediate access to healthcare and their local hospital or doctors office, for initial consultation, scheduling of appointments and follow on care and other added value services that may be one off or recurring.

InnovaQor has agreed to complete the necessary steps and SEC filings with the intent to facilitate TPT shareholders receiving approximately 2,500,000 shares in InnovaQor, and Rennova Health, Inc. shareholders receiving approximately $5M of Preference shares which will be converted to common shares. As described in the agreement TPT will retain direct ownership of a further 2,500,000 shares and Rennova will retain ownership of an additional $17.5M of Preference shares with certain conversion rights and restrictions, in InnovaQor. An additional 1,000,000 shares in InnovaQor will be allocated to TPT or its’ assignees as an incentive to assist in product development.

“Rennova has previously disclosed its intention to separate its technology and software divisions. This agreement with InnovaQor finalizes these plans and the technology being contributed to the project by TPT creates an exciting opportunity to revolutionize the way patients access healthcare and continued aftercare”, said Seamus Lagan, CEO of Rennova Health “We see first-hand the need our rural hospitals have to secure and retain patients. The product envisaged here will create immense value for many health care providers and provide a permanent solution to the current and probably extended reluctance of many people in the current pandemic to visit doctors’ practices and hospitals for initial consultations. A phone based product that reduces a delay in access to healthcare and better manages ongoing care will save lives”

About Rennova Health, Inc.

Rennova operates three rural hospitals and a physician’s office in Tennessee and a physician’s office in Kentucky and provides industry-leading diagnostics and supportive software solutions to healthcare providers. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts:

Rennova Health
Sebastien Sainsbury, 561-666-9818
[email protected]

# # #



ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Investigation of Securities Claims Against OrthoPediatrics Corp.; Encourages Investors with Losses in Excess of $100K to Contact Firm – KIDS

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of OrthoPediatrics Corp. (NASDAQ: KIDS) resulting from allegations that OrthoPediatrics may have issued materially misleading business information to the investing public.

On December 2, 2020, Culper Research published a report entitled “OrthoPediatrics Corp. (KIDS): Even Channel Stuffing Can’t Save This Company[.]” The report alleged that the Company has “engaged in a channel stuffing scheme that has systematically and significantly overstated revenues.” On this news, the Company’s stock price fell $5.40 per share, or 12%, to close at $39.35 per share on December 3, 2020.

Then on December 14, 2020, Culper Research published a second report entitled “OrthoPediatrics Corp. (KIDS): Pleading the Fifth” in which it concluded that the Company “is a structurally broken business which has relied on nefarious tactics to inflate its reported revenues.”

Rosen Law Firm is preparing a securities lawsuit on behalf of OrthoPediatrics shareholders. If you purchased securities of OrthoPediatrics please visit the firm’s website at http://www.rosenlegal.com/cases-register-2015.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Northern Dynasty Minerals Ltd. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

PR Newswire

LOS ANGELES, Jan. 6, 2021 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Northern Dynasty Minerals Ltd. (“Northern Dynasty” or “the Company”) (NYSE: NAK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between December 21, 2017 and November 25, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before February 2, 2021. 

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Northern Dynasty’s Pebble Project was at odds with the guidelines of the Clean Water Act as well as the public interest. The Company’s plan for the Pebble Project was larger in scope and longer in duration than what it conveyed to the public. Due to these facts, the U.S. Army Corps of Engineers would deny the Company’s permit applications for the Pebble Project. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Northern Dynasty, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/upcoming-deadline-alert-the-schall-law-firm-announces-the-filing-of-a-class-action-lawsuit-against-northern-dynasty-minerals-ltd-and-encourages-investors-with-losses-in-excess-of-500-000-to-contact-the-firm-301202035.html

SOURCE The Schall Law Firm

Truck Customers Make F-Series America’s Best-Selling Pickup For 44 Straight Years; Ford Brand Achieves 11 Straight Years as America’s Best-Selling Brand; Ford Explorer Claims Top Spot in 2020

Truck Customers Make F-Series America’s Best-Selling Pickup For 44 Straight Years; Ford Brand Achieves 11 Straight Years as America’s Best-Selling Brand; Ford Explorer Claims Top Spot in 2020

Luxury Customers Propel Lincoln SUVs to Highest Sales in 17 Years

DEARBORN, Mich.–(BUSINESS WIRE)–
Ford Motor Company (NYSE: F) today reported its fourth quarter 2020 U.S. sales results. Click here or visit media.ford.com to view the news release.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005486/en/

About Ford Motor Company

Ford Motor Company (NYSE: F) is a global company based in Dearborn, Michigan. The company designs, manufactures, markets and services a full line of Ford cars, trucks, SUVs, electrified vehicles and Lincoln luxury vehicles, provides financial services through Ford Motor Credit Company and is pursuing leadership positions in electrification; mobility solutions, including self-driving services; and connected services. Ford employs approximately 187,000 people worldwide. For more information regarding Ford, its products and Ford Motor Credit Company, please visit corporate.ford.com.

Media

Said Deep

1.313.594.0942

[email protected]

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Aftermarket Automotive Other Automotive General Automotive Tires & Rubber Recreational Vehicles Performance & Special Interest Alternative Vehicles/Fuels Off-Road Trucks & SUVs Motorcycles Fleet Management

MEDIA:

Logo
Logo

Tejon Ranch Co. Approved to Develop Multi-family Residential Complex

Tejon Ranch Co. Approved to Develop Multi-family Residential Complex

Series of apartment buildings to be located adjacent to the Outlets at Tejon

TEJON RANCH, Calif.–(BUSINESS WIRE)–
Tejon Ranch Co. (NYSE: TRC) announced today the Kern County Board of Supervisors has approved two Conditional Use Permits (CUPs) which will authorize development of multi-family apartment uses within the Tejon Ranch Commerce Center.

The approved CUPs authorize the Company to develop up to a maximum of 495 multi-family residences, in thirteen (13) apartment buildings, as well as approximately 6,500 square feet of community amenity space and 8,000 square feet of community serving retail on the ground floor of a portion of the residential buildings. The development would be located on a 27-acre site located immediately north of the Outlets at Tejon.

About Tejon Ranch Co.

Tejon Ranch Co. (NYSE: TRC) is a growth-oriented, fully diversified real estate development and agribusiness company, whose principal asset is its 270,000-acre land holding located approximately 60 miles north of Los Angeles and 30 miles south of Bakersfield. Tejon Ranch Co. is positioned for growth with its fully operational commercial/industrial real estate development and three master planned residential communities on the horizon.

Barry Zoeller, Senior Vice President, Corporate Communications & Investor Relations

[email protected]

(661) 663-4212

 

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Zynex Announces a Second Utility Patent for Its Blood Volume Monitor

PR Newswire

ENGLEWOOD, Colo., Jan. 6, 2021 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported it has obtained a second U.S. Utility patent for its Blood Volume Monitor Device. Thomas Sandgaard, the inventor, has assigned the patent to Zynex’s subsidiary, Zynex Monitoring Solutions.

Thomas Sandgaard, CEO of Zynex said: “I am excited to receive additional patent protection for our non-invasive blood volume/blood loss technology. Not only are our algorithms well protected but the core principles of detecting body fluid imbalances in hospital settings are now even better protected.

We believe our non-invasive, easy-to-operate technology will serve a huge unmet need to manage patient blood volume in surgical settings, including internal bleeding in recovery and intensive care units. Our first generation CM-1500 device is cleared by the FDA and already in full production.”

About Zynex, Inc.
 
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements.  The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2019 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Zynex, Inc.  (800) 495-6670 

Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zynex-announces-a-second-utility-patent-for-its-blood-volume-monitor-301201821.html

SOURCE Zynex

CETY Completes Setup Of Wholly Owned Subsidiary In Hainan Island, China

PR Newswire

COSTA MESA, Calif., Jan. 6, 2021 /PRNewswire/ — Clean Energy Technologies, Inc. (OTCQB: CETY), a clean energy company focusing on products and solutions in the energy efficiency and environmental sustainability market, announced today CETY has completed the establishment of its wholly owned subsidiary in Hainan Island, China, to take advantage of the tariff free trade zone, which sets the foundation of China Market expansion.

On June 1, 2020, the Chinese government released a master plan for polices to build Hainan Island, on China’s south coast, into a globally significant free-trade port by 2050. Policies will be rolled out to facilitate trade, liberalize investment, allow capital to flow freely cross-border, make transit more convenient for people, and ensure the secure flow of data. Improvements to the taxation and legal systems will be made to support the development of high-tech industries, tourism, and modern services. 

HAINAN Clean Energy Technologies, Inc. is currently in discussions with Shenzhen Natural Gas to provide pilot project in a waste to power application for hospital organic waste. The wholly owned subsidiary is planned to be used as a special purpose vehicle to support CETY’s global clean energy projects including waste heat to power and waste to energy with energy services agreement to design, build, own and operate clean energy plants.

“China is the biggest market for Clean Energy, and we expect substantial growth from Asia pacific region due to high industrialization. With the establishment of our wholly owned subsidiary and the recent agreements with two major partners we feel optimistic about our expansion and scaling up the business in the region,” said Kam Mahdi, CEO of CETY.

For more information, visit www.heatrecoverysolutions.com and www.corycos.com

About Clean Energy Technologies, Inc. (CETY)

Headquartered in Costa Mesa, California, Clean Energy Technologies (CETY) delivers power from heat and biomass with zero emission and low cost. CETY designs, produces and markets clean energy products & solutions focused on energy efficiency and renewable energy. The Company’s principal product is the Clean Cycle™ magnetic bearing heat recovery generator, offered by CETY’s subsidiary Clean Energy HRS, or Heat Recovery Solutions.

The Clean Cycle™ system captures waste heat from a variety of sources and turns it into electricity that can be used or sold back to the grid. CETY’s proven, reliable technology allows municipal, commercial, and industrial users with heat sources, such as from biomass, industrial processes or energy production, to boost their overall energy efficiency with no additional fuel, no pollutants, and little ongoing maintenance. CETY’s common stock is currently traded on the OTC Market under the symbol CETY.

For more information, visit www.cetyinc.com or www.heatrecoverysolutions.com.

DISCLAIMER

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.

Contact:
Clean Energy Technologies, Inc.
Kam Mahdi, CEO
949-273-4990 x814
[email protected]

Clean Energy Technologies, Inc.
2990 Redhill Avenue
Costa Mesa , CA 92626
949.273.4990 main
949.273.4990 fax
www.cetyinc.com

 

Cision View original content:http://www.prnewswire.com/news-releases/cety-completes-setup-of-wholly-owned-subsidiary-in-hainan-island-china-301201425.html

SOURCE Clean Energy Technologies, Inc.

Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase $25.2 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $1.055.

Atossa has agreed to sell a total of 23,850,000 shares of common stock and warrants to purchase 17,887,500 shares of common stock. The warrants have an exercise price of $1.055 per share, are exercisable immediately and will expire four and a half years following the date of issuance.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $25.2 million before deducting the placement agent’s fees and other estimated offering expenses. The offering is expected to close on or about January 8, 2021, subject to the satisfaction of customary closing conditions.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333- 248555), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on September 10, 2020. The offering of the shares of common stock, the warrants and the common shares underlying the warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 895-3745.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
[email protected]

Investor Relations Contact:
Core IR
Office:(516) 222-2560
[email protected]



Chicken Soup for the Soul Entertainment to Attend 23rd Annual Needham Virtual Growth Conference

COS COB, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE), one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, today announced that management will attend the 23rd Annual Needham Virtual Growth Conference and will conduct virtual one-on-one and small group meetings from Tuesday, January 12th to Friday, January 15th. Management is also scheduled to participate in a fireside chat on Tuesday, January 12th at 10:00 a.m. ET. A live webcast, as well as a replay, of the fireside chat will be available on the company’s investor relations website at https://ir.cssentertainment.com/.

ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT

Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) operates streaming video-on-demand networks (VOD). The company owns Crackle Plus, which owns and operates a variety of ad-supported and subscription-based VOD networks including Crackle, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Españolflix and FrightPix. The company also acquires and distributes video content through its Screen Media subsidiary and produces original long and short-form content through Landmark Studio Group, its Chicken Soup for the Soul Originals division and APlus.com. Chicken Soup for the Soul Entertainment is a subsidiary of Chicken Soup for the Soul, LLC, which publishes the famous book series and produces super-premium pet food under the Chicken Soup for the Soul brand name.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the nine-month period ended September 30, 2020) and uncertainties which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

INVESTOR RELATIONS
Taylor Krafchik
Ellipsis
[email protected]
(646) 776-0886

MEDIA CONTACT
Kate Barrette
RooneyPartners LLC
[email protected]
(212) 223-0561



JFrog to Present at the 23rd Annual Needham Virtual Growth Conference

SUNNYVALE, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — JFrog Ltd. (“JFrog”) (NASDAQ: FROG), the liquid software company, today announced that Shlomi Ben Haim, Co-Founder and CEO, and Jacob Shulman, CFO, will present at the 23rd Annual Needham Virtual Growth Conference on Tuesday, January 12, 2021 at 2:00 pm ET / 11:00 am PT.

The live webcast and replay will be available on the Company’s investor relations website at https://investors.jfrog.com/events-and-presentations/events.

About JFrog

JFrog is on a “Liquid Software” mission to enable the flow of software seamlessly and securely from the developer’s keystrokes to production. The end-to-end, hybrid JFrog Platform provides the tools and visibility required by modern software development organizations to fully embrace the power of DevOps. JFrog’s universal, multi-cloud DevOps platform is available as open-source, self-managed, and SaaS services on AWS, Microsoft Azure, and Google Cloud. JFrog is trusted by millions of users and thousands of customers, including a majority of the Fortune 100 companies that depend on JFrog solutions to manage their mission-critical software delivery pipelines. JFrog has offices across North America, Europe, and Asia. Learn more at jfrog.com.

Investor Contact:
JoAnn Horne
[email protected]
415-445-3240